Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
It is a drug that decreases elevated plasma levels of glutamine and ammonium in patients with urea cycle disorders. Oral administration before meals.
Since the last update we have not found published data on its excretion in breastmilk.
Its rapid metabolism to phenylacetate and short elimination half-life make it highly unlikely that clinically significant amounts will pass into breast milk.
It is a medication for use since the neonatal period.
With the correct dosage, side effects are not frequent or serious. The possibility of breastfeeding will depend more on the underlying disease and the clinical status of the mother.